Publications by authors named "Tim Overend"

Claim this Profile
E
Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial.
Gernot Rohde, Stephan Stenglein, Hans Prozesky, Ganesh Manudhane, Oana Sandulescu, Tim Overend

EClinicalMedicine· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-interventional study of the safety and effectiveness of fluticasone propionate/formoterol fumarate in real-world asthma management.
Vibeke Backer, Adam Ellery, Sylvia Borzova, Stephen Lane, Magda Kleiberova, Tim Overend

Ther Adv Respir Dis· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies.
Anthony D'Urzo, Edward Kerwin, Tim Overend, Peter D'Andrea, Hungta Chen

Curr Med Res Opin· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study.
Kenneth R Chapman, Kai-Michael Beeh, Jutta Beier, Eric D Bateman, Anthony D'Urzo, Tim Overend

BMC Pulm Med· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
Helen Arievich, Tim Overend, Didier Renard, Michael Gibbs, Vijay Alagappan

BMC Pulm Med· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.
Edward Kerwin, Jacques Hébert, Nicola Gallagher, Carmen Martin, Tim Overend

Eur Respir J· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial.
Anthony D'Urzo, Gary T Ferguson, Jan A van Noord, Kazuto Hirata, Carmen Martin, Tim Overend

Respir Res· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
Jan A van Noord, Roland Buhl, Craig Laforce, Carmen Martin, Francis Jones, Tim Overend

Thorax· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
Boudewijn Van de Maele, Leonardo M Fabbri, Carmen Martin, Rachael Horton, Michael Dolker, Tim Overend

COPD· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of formoterol on exercise tolerance in severely disabled patients with COPD.
J Alberto Neder, Jonathan P Fuld, Tim Overend, Jackie Thirlwell, Roger Carter

Respir Med· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility.
Demosthenes Bouros, John Kottakis, Vincent Le Gros, Tim Overend, Giovanni Della Cioppa

Curr Med Res Opin· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study.
John Kottakis, Giovanni Della Cioppa, Jacques Creemers, Louis Greefhorst, Violette Lecler, Tim Overend

Can Respir J· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis